EC145 Overian Phase IIIEC145 Small Lung Phase II2bEC145 3rd New Application TreatmentEC145 4thEC145 5thEC145 6thAll this year / begin of 2013 and Merck will pay880 mln Milestone239 mln Cash / $6,9050% of US ProfitsDouble Digit Profit non US -EC 145Very Good FPS results in FR++Rest of PipelineEC20Tell me, what am I missing?
looks like institution buying is picking up now
yes, some MM started buying, great, this should be close to $10 soon soon.
EC0531 folate-tubulysin, solide tumorsPSMA-tubulysin, prostate cancerPSMA-Tc99m prostate cancer imagingEC0746 and EC0565, folate-drug conjugates, anti-inflammation
and very soon another deposit of $120mln for just small lung, EC 145 Ovarianmilestone for EU approval, will be huge alsosmall milestones for the four new different application of EC145 of cancer threatments$17 sooner, than many expect, and even then this company is way undervalued